Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
About this item
Full title
Author / Creator
Roberts, Andrew W , Davids, Matthew S , Pagel, John M , Kahl, Brad S , Puvvada, Soham D , Gerecitano, John F , Kipps, Thomas J , Anderson, Mary Ann , Brown, Jennifer R , Gressick, Lori , Wong, Shekman , Dunbar, Martin , Zhu, Ming , Desai, Monali B , Cerri, Elisa , Heitner Enschede, Sari , Humerickhouse, Rod A , Wierda, William G and Seymour, John F
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective that precautions are necessary to protect patients against the tumor lysis syndrome at therapy initiation.
The landscape of treatment for relapsed chronic lymphocytic leukemia (CLL) has rece...
Alternative Titles
Full title
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Authors, Artists and Contributors
Author / Creator
Davids, Matthew S
Pagel, John M
Kahl, Brad S
Puvvada, Soham D
Gerecitano, John F
Kipps, Thomas J
Anderson, Mary Ann
Brown, Jennifer R
Gressick, Lori
Wong, Shekman
Dunbar, Martin
Zhu, Ming
Desai, Monali B
Cerri, Elisa
Heitner Enschede, Sari
Humerickhouse, Rod A
Wierda, William G
Seymour, John F
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7107002
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7107002
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1513257
